Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease

Hao-jian Dong1, Cheng Huang1, De-mou Luo1, Jing-guang Ye1, Jun-qing Yang1, Guang Li1, Jian-fang Luo1, Ying-ling Zhou1
1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academic of Medical Sciences, Guangzhou, China

Tóm tắt

Percutaneous transluminal renal artery stenting (PTRAS) has been proved to have no more benefit than medication alone in treating atherosclerotic renal artery stenosis (ARAS). Whether PTRAS could improve left ventricular hypertrophy (LVH) and reduce adverse events when based on percutaneous coronary intervention (PCI) for patients with coronary artery disease (CAD) and ARAS is still unclear. A retrospective study was conducted, which explored the effect of concomitant PCI and PTRAS versus PCI alone for patients with CAD and ARAS complicated by heart failure with preserved ejection fraction (HFpEF). A total of 228 patients meeting inclusion criteria were divided into two groups: (1) the HFpEF-I group, with PCI and PTRAS; (2) the HFpEF-II group, with PCI alone. Both groups had a two-year follow-up. The left ventricular mass index (LVMI) and other clinical characteristics were compared between groups. During the follow-up period, a substantial decrease in systolic blood pressure (SBP) was observed in the HFpEF-I group, but not in the HFpEF-II group. There was marked decrease in LVMI in both groups, but the HFpEF-I group showed a greater decrease than the HFpEF-II group. Regression analysis demonstrated that PTRAS was significantly associated with LVMI reduction and fewer adverse events after adjusting for other factors. In HFpEF patients with both CAD and ARAS, concomitant PCI and PTRAS can improve LVH and decrease the incidence of adverse events more than PCI alone. This study highlights the beneficial effect of ARAS revascularization, as a new and more aggressive revascularization strategy for such high-risk patients.

Từ khóa


Tài liệu tham khảo

Asrar ul Haq, M., Wong, C., Mutha, V., et al., 2014. Therapeutic interventions for heart failure with preserved ejection fraction: a summary of current evidence. World J. Cardiol., 6(2):67–76. http://dx.doi.org/10.4330/wjc.v6.i2.67 Chábová, V., Schirger, A., Stanson, A.W., et al., 2000. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin. Proc., 75(5):437–444. http://dx.doi.org/10.4065/75.5.437 Chobanian, A.V., Bakris, G.L., Black, H.R., et al., 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6):1206–1252. http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2 Cooper, C.J., Murphy, T.P., Cutlip, D.E., et al., 2014. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N. Engl. J. Med., 370(1):13–22. http://dx.doi.org/10.1056/NEJMoa1310753 Dean, R.H., Kieffer, R.W., Smith, B.M., et al., 1981. Renovascular hypertension: anatomic and renal function changes during drug therapy. Arch. Surg., 116(11):1408–1415. http://dx.doi.org/10.1001/archsurg.1981.01380230032005 de Silva, R., Nikitin, N.P., Bhandari, S., et al., 2005. Atherosclerotic renovascular disease in chronic heart failure: should we intervene? Eur. Heart J., 26(16):1596–1605. http://dx.doi.org/10.1093/eurheartj/ehi304 Ding, J., Xu, H., Yin, X., et al., 2014. Estrogen receptor a gene PvuII polymorphism and coronary artery disease: a metaanalysis of 21 studies. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(3):243–255. http://dx.doi.org/10.1631/jzus.B1300220 Folland, E.D., Parisi, A.F., Moynihan, P.F., et al., 1979. Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation, 60(4):760–766. http://dx.doi.org/10.1161/01.CIR.60.4.760 Ghanami, R.J., Rana, H., Craven, T.E., et al., 2011. Diastolic function predicts survival after renal revascularization. J. Vasc. Surg., 54(6):1720–1726. http://dx.doi.org/10.1016/j.jvs.2011.05.091 Groban, L., Kitzman, D.W., 2010. Diastolic function: a barometer for cardiovascular risk? Anesthesiology, 112(6):1303–1306. http://dx.doi.org/10.1097/ALN.0b013e3181da89e4 Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., et al., 2006. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J. Am. Coll. Cardiol., 47(6):1239–1312. http://dx.doi.org/10.1016/j.jacc.2005.10.009 Kane, G.C., Xu, N., Mistrik, E., et al., 2010. Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol. Dial. Transplant., 25(3):813–820. http://dx.doi.org/10.1093/ndt/gfp393 Levy, D., Garrison, R.J., Savage, D.D., et al., 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med., 322(22):1561–1566. http://dx.doi.org/10.1056/NEJM199005313222203 Little, W.C., Brucks, S., 2005. Therapy for diastolic heart failure. Prog. Cardiovasc. Dis., 47(6):380–388. http://dx.doi.org/10.1016/j.pcad.2005.02.004 Liu, X.B., Jiang, J.B., Zhou, Q.J., et al., 2015. Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(3):208–214. http://dx.doi.org/10.1631/jzus.B1500017 Marcantoni, C., Zanoli, L., Rastelli, S., et al., 2012. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am. J. Kidney Dis., 60(1):39–46. http://dx.doi.org/10.1053/j.ajkd.2012.01.022 McMurray, J.J., Adamopoulos, S., Anker, S.D., et al., 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 14(8):803–869. http://dx.doi.org/10.1093/eurjhf/hfs105 Middleton, R.J., Parfrey, P.S., Foley, R.N., 2001. Left ventricular hypertrophy in the renal patient. J. Am. Soc. Nephrol., 12(5):1079–1084. Park, S., Jung, J.H., Seo, H.S., et al., 2004. The prevalence and clinical predictors of atherosclerotic renal artery stenosis in patients undergoing coronary angiography. Heart Vessels, 19(6):275–279. http://dx.doi.org/10.1007/s00380-004-0789-1 Patel, S.S., Kimmel, P.L., Singh, A., 2002. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin. Nephrol., 22(6):449–458. Przewlocki, T., Kablak-Ziembicka, A., Tracz, W., et al., 2008. Renal artery stenosis in patients with coronary artery disease. Kardiol. Pol., 66(8):856–862, 863–864. Ronco, C., di Lullo, L., 2014. Cardiorenal syndrome. Heart Fail. Clin., 10(2):251–280. http://dx.doi.org/10.1016/j.hfc.2013.12.003 Simon, J.F., 2010. Stenting atherosclerotic renal arteries: time to be less aggressive. Cleve. Clin. J. Med., 77(3):178–189. http://dx.doi.org/10.3949/ccjm.77a.09098 Su, C.S., Liu, T.J., Tsau, C.R., et al., 2013. The feasibility, safety, and mid-term outcomes of concomitant percutaneous transluminal renal artery stenting in acute coronary syndrome patients at high clinical risk of renal artery stenosis. J. Invasive Cardiol., 25(5):212–217. Wang, X., Shi, L.Z., 2014. Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: a meta-analysis. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(3):256–263. http://dx.doi.org/10.1631/jzus.B1300088 Wheatley, K., Ives, N., Gray, R., et al., 2009. Revascularization versus medical therapy for renal-artery stenosis. N. Engl. J. Med., 361(20):1953–1962. http://dx.doi.org/10.1056/NEJMoa0905368 Wright, J.R., Shurrab, A.E., Cooper, A., et al., 2005. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J. Am. Soc. Nephrol., 16(9):2746–2753. http://dx.doi.org/10.1681/ASN.2005010043